Laurence E. Burgess
Vividion Therapeutics (United States) · 73 works · 2,078 citations · h-index 21
Top works
- A simple asymmetric synthesis of 2-substituted pyrrolidines and 5-substituted pyrrolidinones
- Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- Asymmetric synthesis of .gamma.,.gamma.-dialkyl-.gamma.-aminobutyric acid analogs and 2,2-disubstituted pyrrolidines. Control of stereochemistry in aminal ring opening by varying the extent of allylic 1,3 strain
- A simple asymmetric synthesis of 2-substituted pyrrolidines from 3-acylpropionic acids
- The preparation of α-substituted, β-hydroxy piperidines and pyrrolidines: The total synthesis of febrifugine
- Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists
- UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation
- Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
- Potent selective nonpeptidic inhibitors of human lung tryptase
- Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy}-pentane (AMG-126737)
- Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
- Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors
- Novel approach to the ansamycin antibiotics macbecin I and herbimycin A. A formal total synthesis of (+)-macbecin I
- Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-α, IL-6 and IL-1β: possible relevance to multiple sclerosis
- Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists
- The SAR of UK-78,282: A novel blocker of human T cell Kv1.3 potassium channels
- An asymmetric synthesis of novel aminocyclopropyl carboxylic acids (ACC)
- A formal total synthesis of (+)-macbecin I
- Mast cell tryptase as a target for drug design
- Strategies for ansamycin antibiotics. asymmetric synthesis of the C(3)–C(21) subunit of herbimycin A